ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings

August 16, 1985

In Brief: First Peer-Reviewed Comprehensive Centers Named; Sawaya To Lead Anderson Neurosurgery

October 5, 1990

Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm

November 28, 2014

In Brief: White House Appoints Six to NCAB; Calabrisi To Succeed Korn As Chairman; 2 Spaces Vacant

January 25, 1991

Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma

December 31, 2010

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003